About Management of Cough in Patients with Community-acquired Pneumonia: the Results of MUCASTAT PLUS Trial
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The objective: to study an effectiveness and tolerability of free prescription by physicians of erdostein and ambroxol for management of cough in hospitalized patients with non-severe community-acquired pneumonia on the background of standard antibacterial treatment after completion of MUCASTAT trial.
Materials and methods. 245 patients (110 men and 135 women) aged 21–82 years were included in an open prospective non-randomized study. All the patients received standard antibacterial treatment for 7–10 days and mucoactive drugs of erdosteine (Mucitus) or ambroxol in standard dosages for no less then 6 days. CAP-Sym-12 and Scale of Estimation of CAP (SECAP) questionnaires were used to estimate pneumonia-related symptoms.
Results. In 2–3 days from the beginning of therapy the patients from erdosteine group began to estimate their well-being (condition) and cough intensity (according to CAP-Sym-12 questionnaire) better, than patients from ambroxol group. In subsequent observation periods (in 7±1 and 12±2 days from the beginning of treatment) superiority of erdosteine was documented by objective (lesser quantity of patients suffering from cough and sputum expectoration) and subjective methods (CAP-Sym-12 and SECAP questionnaires).
Conclusion. An effectiveness, good tolerability and superiority of erdosteine over ambroxol for management of cough and sputum expectoration in hospitalized patients with community acquired pneumonia on the background of standard antibacterial treatment were confirmed in MUCASTAT PLUS study.##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Guidelines for the management of adult lower respiratory tract infections / M. Woodhead, F. Blasi, S. Ewig [et al.] // Clin. Microbiol. Infect. – 2011. – Vol. 17, Suppl. 6. – P. E1–E59.
Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America / J.P. Metlay, G.W. Waterer, A.C. Long [et al.] // Am. J. Respir. Crit. Care Med. – 2019. – Vol. 200. – No. 7. – P. e45–e67.
National Institute for Health and Care Excellence. Pneumonia (communityacquired): antimicrobial prescribing. 2019. Доступно по адресу: www.nice.org.uk/guidance/ng138
National Institute for Health and Care Excellence. Pneumonia (including community-acquired pneumonia). 2014. Доступно по адресу: www.nice.org.uk/guidance/cg191
Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults / C.C. Chang, A.C. Cheng, A.B. Chang // Cochrane Database Syst. Rev. – 2012. – Issue 2. – Art. No.: CD006088.
Эффективность эрдостеина для лечения кашля у больных внебольничными пневмониями: результаты исследования МУКАСТАТ / И.Г. Березняков, М.Н. Лебединская, В.И. Березняков, И.Д. Ломино // Сімейна медицина. – 2017. – № 4 (72). – С. 100–104.
Махаринська О.С. Застосування та валідизація короткого опитувальника для хворих на негоспітальну пневмонію в Україні / Махаринська О.С., Лебединська М.М., Березняков І.Г. // Болезни и антибиотики. – 2012. – № 1. – С. 51–58.
Березняков І.Г. Особливості перебігу нетяжкої негоспітальної пневмонії у осіб із супутньою хронічною серцевою недостатністю / І.Г. Березняков, М.М. Лебединська // Болезни и антибиотики. – 2013. – № 1. – С. 36–48.
Корж А.Н. Эффективность ступенчатой терапии у больных с внебольничными пневмониями с сопутствующей хронической сердечной недостаточностью / А.Н. Корж, В.И. Березняков // Болезни и антибиотики. – 2013. – № 1. – С. 13–22.
Adult outpatients with acute cough due to suspected pneumonia or influenza. CHEST Guideline and Expert Panel Report / A.T. Hill, P.M. Gold, A.A. El Solh [et al.] // Chest. – 2019. – Vol. 155. – No. 1. – P. 155–167.
Clinical effectiveness of a combination of bromhexine and amoxicillin in lower respiratory tract infection. A randomized controlled trial / C.C. Jr. Roa, R.B. Dantes // Fortschritte der Arzneimittelforschung. – 1995. – Vol. 45, № 3. – P. 267–72.
Moretti M. Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease // Expert. Rev. Resp. Med. – 2007. – Vol. 1, No. 3. – P. 307–316.
Cazzola M. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data / M. Cazzola, I. Floriani, C.P. Page // Pulmon. Pharmacol. Ther. – 2010. – V. 23. – No. 2. – P. 135–144.
Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study / R.W. Dal Negro, J.A. Wedzicha, M. Iversen M [et al.] // Eur. Respir. J. – 2017. – Vol. 50. – P. 1700711.
Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine / P. Rogliani, M.G. Matera, C. Page [et al.] // Respir. Research. – 2019. – Vol. 20. – P. 104.
